Back to discover
Disease
Demyelinating Autoimmune Diseases, CNS
Late-stage therapeutic developmentEmerging research
1
Publications
2
Clinical trials
2018
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Research2017-11-15Journal of neurology, neurosurgery, and psychiatry
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
No activity recorded in this window. Try a wider timeframe.
Clinical trials
The current development programme across all trial phases.
Clinical programme
2
1
2
1
Late-stage studies
Recruiting
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Most influential
Leading journals1
- Journal of neurology, neurosurgery, and psychiatry1
Leading researchers8
- Barnett MH1
- Brilot F1
- Broadley S1
- Dale RC1
- Fung VSC1
- Henderson APD1
- Lechner-Scott J1
- Merheb V1
Affiliations (unnormalised)6
- Brain and Mind Centre1
- Children's Hospital1
- Department of Clinical Medicine1
- Gold Coast University Hospital1
- Hunter Medical Research Institute1
- Institute for Neuroscience and Muscle Research1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Conditions characterized by loss or dysfunction of myelin (see MYELIN SHEATH) in the brain, spinal cord, or optic nerves secondary to autoimmune mediated processes. This may take the form of a humoral or cellular immune response directed toward myelin or OLIGODENDROGLIA associated autoantigens.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.